Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Block

Teladoc

These Cathie Wood Stocks have their risks but offer a massive upside potential ahead The post 3 Cathie Wood Stocks to Count on in Q2 appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn't matter if you have $500 in savings or $5 million.

3 Cathie Wood Stocks to Count on in Q2

BioMarin Pharmaceutical

Intercept Pharma

Ionis Pharma

Mirati Therapeutics

Novartis

Sarepta Therapeutics

Big biopharma companies usually rely on M&A to get immediate access to a new class of drug or technology, fill in the gap in their pipeline and compensate for revenue loss from patent expiration of blockbuster products. The post 7 Potential Biotech Stocks Buyout Targets in 2022 appeared first on InvestorPlace.

7 Potential Biotech Stocks Buyout Targets in 2022

Editas Medicine

Intellia Therapeutics

They point to trouble for investors counting on a rebound.

3 Ominous Reasons to Avoid This Biotech Pioneer

This company's targeting a market with explosive growth.

Is Now the Time to Bet on This Game-Changing Stock?

The only thing standing in the way is the clinical trials process, which takes time and patience.

CRISPR Stocks Are Huge -- Here's Why They'll Get Even Bigger by 2030

Abbott Labs

Thermo Fisher Scientific

Thinking about digging into immunization stocks? Let's look more broadly, into life sciences stocks.

3 Best Life Sciences Stocks to Buy Now

Etsy

Lockheed Martin

MP Materials

Moderna

Micron Technology

Seagen

Upstart Holdings

YUM! Brands

Some of these stocks present long opportunities as they pull back.

9 Wave Setups To Watch (Video)

Novavax

3 Ultra-Popular Stocks That Could Soar 120%, 51%, and 109%, Wall Street Says

Chevron

Get past the persistently bearish headlines, and you'll find stocks to trade long in emerging bull markets that could be lucrative. The post 3 Best Stocks to Trade Right Now appeared first on InvestorPlace.

3 Best Stocks to Trade Right Now

CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock?

CRISPR Therapeutics AG (CRSP) Up 5.8% Since Last Earnings Report: Can It Continue?

Barclays

Crispr Therapeutics AG's (CRSP) CEO Sam Kulkarni Presents at Barclays Global Healthcare Conference (Transcript)

The biotech stock is making gains despite market pressures, but it's still down roughly 71% from its high.

Why CRISPR Therapeutics Stock Soared This Week

DraftKings

These most-shorted stocks have investors seeing red, but there is a silver lining that's playing out on the price chart for today's buyers. The post 3 Ark Invest Most-Shorted Stocks to Buy appeared first on InvestorPlace.

3 Ark Invest Most-Shorted Stocks to Buy

Shopify

Don't buy Cathie Wood stocks because the market was singing on Wednesday, purchase them because of a much bigger and bullish picture. The post 3 Cathie Wood Stocks to Buy appeared first on InvestorPlace.

3 Cathie Wood Stocks to Buy

Recent comments from the company's CEO are prompting bullish momentum for the stock.

CRISPR Therapeutics Stock Surged Today: Is It a Buy?

ZUG, Switzerland and CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that it will present an e-poster at the American Association for Cancer Research (AACR) 2022 Annual Meeting, taking place April 8-13, 2022, at the Ernest N. Morial Convention Center in New Orleans, Louisiana, and online.

CRISPR Therapeutics Announces Poster Presentation at the American Association for Cancer Research 2022 Annual Meeting

Despite big gains today, the biotech specialist's share price is still down roughly 46% over the past year of trading.

Why CRISPR Therapeutics Stock Is Soaring Today

Cowen

CRISPR Therapeutics' (CRSP) CEO Sam Kulkarni on Cowen 42nd Annual Health Care Conference (Transcript)

CRISPR Therapeutics' share price has fallen by half across the past 12 months - although the company is making solid progress and may soon win approval in Sickle Cell Disease.

CRISPR Therapeutics - Progress Adds More Value Than Patent Setback Subtracts

Nu Holdings

Vertex Pharmaceuticals

Buffett's latest letter to Berkshire Hathaway shareholders revealed the legendary investor's present mindset.

Should You Buy Stocks Now? Here's What Warren Buffett Thinks

Peloton

Chewy

Electronic Arts

Matterport

Boston Beer Company

Scotts Miracle-Gro

Savvy investors can generate lucrative returns by investing in companies that look like prime takeover targets. This article speculates on a number of takeover targets of 2022.

Peloton Isn't the ONLY Takeover Target. What Companies Could Be Bought Out in 2022?

CRISPR Therapeutics (CRSP) reports wider-than-expected Q4 loss. Nonetheless, revenues beat estimates.

CRISPR Therapeutics (CRSP) Q4 Earnings Miss, Revenues Up Y/Y

CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of -5.75% and 139.40%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

CRISPR Therapeutics AG (CRSP) Reports Q4 Loss, Tops Revenue Estimates

- More than 70 patients have been dosed with CTX001™ across CLIMB-Thal-111 and CLIMB-SCD-121 to date; enrollment complete and regulatory submissions planned for late 2022-

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

Sangamo Therapeutics

Our theme of Gene Editing stocks continues to underperform, declining by about 16% year-to-date in 2022, compared to the S&P 500 which is down by about 6% over the same period. The theme also declined by about 11% in 2021.

The Sell Off In Gene Editing Stocks Continues. Time To Buy?

News for CRISPR Therapeutics Stock (CRSP)